Digest Network Come funziona
Network
/
Società
Ad
Non verificato

Aditxt, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

59 comunicati stampa

Guarda tutti i comunicati
20/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
19/03/2026
Scienza
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
13/03/2026
Eventi
Mercato azionario
Scienza
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Oncologia
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
05/03/2026
Finanza
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Tecnica
Salute
Finanza
Sanità
Associazioni/Professionisti
Oncologia
Scienza
Software
Titoli e azioni
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
29/10/2025
Salute
Scienza
Farmaceutica
Biotecnologia
Finanza
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
27/10/2025
Sanità
Vetrine/Shopping
Salute
Medicina - Varie
Industria
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
25/08/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
11/08/2025
Associazioni/Professionisti
Salute
Biotecnologia
Mercato del lavoro
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0
29/07/2025
Biotecnologia
Salute
Oncologia
Titoli e azioni
Mercato del lavoro
Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
Fonte
Aditxt, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0